Biosecurity Modernization and Innovation Act
US Senate bill requiring gene-synthesis providers to screen orders against AI-designed hazardous biological sequences.
Last refreshed: 9 June 2026 · Appears in 1 active topic
Does the Biosecurity Modernization Act cover AI-designed pathogen sequences, not just known ones?
- What does the Biosecurity Modernization and Innovation Act do?
- S.3741 would require US gene-synthesis companies to screen all orders against a federal database of hazardous sequences, including AI-designed variants, and report flagged orders to federal authorities.
- Why are existing DNA synthesis screening rules not enough?
- Current voluntary screening only flags sequences closely matching known pathogens. S.3741 targets the gap where AI tools can design novel hazardous sequences that do not closely resemble anything in existing databases.
- Has the Biosecurity Modernization Act passed in 2026?
- As of June 2026 the bill (S.3741) remained in Senate committee and had not been enacted into law.
Background
The Biosecurity Modernization and Innovation Act (S.3741) is a US Senate bill introduced in January 2026 mandating DNA and gene-synthesis providers to screen every order against a federal registry of hazardous sequences, including sequences generated or modified by AI tools. The bill's core requirements include compulsory pre-synthesis screening, mandatory reporting of flagged orders, consolidation of biosecurity oversight across agencies, and minimum security standards for synthesis equipment. Proponents argue that existing voluntary protocols cover only close matches to known pathogens, not novel AI-designed variants. As of June 2026 the bill remained in Senate committee.
